- Trial phase
- Phase 3
- Time to market
- The Phase 3 RADIANT program's estimated primary completion is January 2028 per ClinicalTrials.gov. If Phase 3 succeeds, an NDA submission would follow, putting a potential FDA decision no earlier than late 2028 or 2029.
- Why 4/10
- The next hard catalyst is the CTAD conference presentation (November 16-19, 2026), but this is a detailed data disclosure, not a binary regulatory/pivotal readout. The Phase 3 RADIANT program's estimated primary completion is January 2028, more than 12 months away, so no near-term binary catalyst exists. Acadia has two approved, revenue-generating products (Nuplazid and Daybue, $342M/quarter), so remlifanserin is a major pipeline asset but not the sole driver of company value. Impact score is 4.
Watch the CTAD conference (November 16-19, 2026) for detailed Phase 2 data that could shift sentiment. The key binary catalyst is the Phase 3 RADIANT readout, estimated for January 2028. In the interim, Acadia's quarterly earnings and commercial execution of Nuplazid/Daybue will likely drive the stock more than remlifanserin news. A Phase 3 success could open a multi-billion-dollar ADP market; a failure would remove a key pipeline asset but leave Acadia's approved-product revenue intact.
Price Chart
Executive Summary
Remlifanserin (ACP-204) is Acadia Pharmaceuticals' next-generation 5-HT2A receptor inverse agonist in Phase 3 for Alzheimer's disease psychosis, a condition with no approved therapies. The Phase 2 RADIANT study narrowly missed its primary endpoint (p=0.0603) but showed consistent efficacy signals at the 60 mg dose, leading Acadia to continue Phase 3 with a refined design. The drug also has Fast Track designation from the FDA. With Phase 3 data not expected until early 2028, remlifanserin is a mid-to-long-term pipeline value driver for Acadia, which already generates over $1.3B in annual revenue from Nuplazid and Daybue. The stock trades at $21.23, well below the $30.53 mean analyst target, reflecting uncertainty around the Phase 3 program after the near-miss.
How It Works
Remlifanserin is a small-molecule pill that blocks a specific serotonin receptor (5-HT2A) in the brain. By dampening overactivity at this receptor, it aims to reduce hallucinations and delusions without the motor side effects typical of older antipsychotics. It is a next-generation follow-on to Acadia's approved drug pimavanserin (Nuplazid), designed to be more potent and selective and to avoid the heart-rhythm risk (QT prolongation) that limited pimavanserin.
Trial Status
Remlifanserin is being studied under the RADIANT master protocol (NCT06159673), an operationally seamless Phase 2/3 program in Alzheimer's disease psychosis (ADP). The Phase 2 portion (approx. 318 patients) tested 30 mg and 60 mg once-daily doses vs placebo over 6 weeks. Topline results reported September 24, 2026: the 60 mg dose narrowly missed the primary endpoint (SAPS-H+D, p=0.0603) but hit a key secondary endpoint with nominal significance (CGI-S-ADP, p=0.0077). The 30 mg arm showed minimal benefit. Acadia is continuing two ongoing Phase 3 substudies with only the 60 mg dose and plans to enroll patients with more severe psychosis. A separate Phase 2 trial in Lewy body dementia psychosis (NCT07029581) is also recruiting.
The Two-Sided Case
Upcoming Catalysts
- Detailed Phase 2 RADIANT safety and efficacy data to be presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference, November 16-19, 2026 in Boston.
- Phase 3 RADIANT program amendments and enrollment updates (ongoing).
- Phase 2 Lewy body dementia psychosis trial data readout (timeline not yet disclosed).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report